Developer docs
API playgroundTry for free, no card

Search company profiles

Numedicus

Full company profile

uuid002rljs

Namestring
Numedicus
Legal namestring
Numedicus Limited
Websiteurl
numedicus.co.uk
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Numedicus is a UK-based pharmaceutical company founded in 2008 (first posts 2009) and headquartered in Cambridge, England. The company specializes in drug repurposing (therapeutic switching), using a knowledge-based approach to identify secondary therapeutic uses for compounds that have already been launched, registered, or investigated. Its core asset is the proprietary DrugRepurposing.info database, which catalogues 9,040 compounds, 471 indications, 999 mechanisms, 3,013 mechanism-indication links, 815 compound-indication links, and 273 compound-mechanism (off-target) links, yielding 4,101 candidate repurposing opportunities. The company uses five methods to find new drug uses: bioinformatics-based mathematical association, pharmacology pathway models, off-target pharmacological screening, clinical experimentation, and a knowledge-based approach that bridges to patent-protectable aspects.

The business model is B2B IP licensing and co-development. Numedicus identifies clinical-stage repurposing candidates, secures method-of-use patents, and out-licenses them to pharmaceutical and biotech partners for further development and commercialization. Lead assets include Tianeptine / a glutamate modulator (AMO-04), licensed to AMO Pharma for Rett Syndrome and certain breathing disorders (which received FDA Orphan Drug Designation in July 2018), and espindolol for cancer cachexia, which was contributed to the 2017 Actimed Therapeutics spin-out. Numedicus also works with associated company Exvastat (David Cavalla-founded, kinase inhibitors; Phase II in severe Covid-19 initiated 2020), and historically with PsiOxus on the Phase II MT-102 program. Customer segments span large, mid-size, and specialty pharma, biotech companies seeking life-cycle management or in-licensing opportunities, university pharmacology departments with academic discoveries, drug delivery companies seeking novel actives, and rare disease / orphan drug developers.

The firm operates as a lean, asset-centric, virtual organization: founder and CEO David Cavalla leads the company while also chairing or co-founding several other biotechs (Arachnova Ltd, Exvastat, Serenatis Bio Ltd), and no external equity investors or institutional shareholders are disclosed. Revenue is generated through licensing milestones and royalty-like payments on out-licensed IP, supported by patents including EP2094254B1 (s-pindolol / cancer cachexia) and US8716325 (espindolol for cachexia). Marketing and distribution rely on the DrugRepurposing.info website, a blog covering pharmaceutical strategy and drug repurposing, a newsletter subscription, and a Twitter channel (@numedicus).

Short descriptiontext

Numedicus is a UK-based pharmaceutical company that identifies and patents secondary therapeutic uses for existing drugs, backed by its proprietary DrugRepurposing.info database of 9,040 compounds and 4,101 repurposing opportunities, and licenses these method-of-use patents to pharma and biotech partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersCambridge, United Kingdom
HQ citystring
Cambridge
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug repurposing services, therapeutic switching, pharmaceutical IP licensing, method-of-use patents, drug discovery consulting
Industry1 code
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Drug Repurposing Consulting
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and IP Commercialization
TypeLicensing Royalties
Description

Numedicus generates revenue through licensing its intellectual property (method-of-use patents) to pharmaceutical and biotechnology companies. The company identifies clinical-stage drug repurposing projects, secures patent protection, and licenses them to partners for further development. Examples include licensing to AMO Pharma (Rett Syndrome glutamate modulator) and the spin-out of Actimed Therapeutics for espindolol (cancer cachexia).

numedicus.co.uk
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1DrugRepurposing Online database
Description

Online database featuring over 4,000 potential new uses for existing compounds, containing both existing and abandoned drugs and focused on functional, experimentally validated content. Available at drugrepurposing.info.

numedicus.co.uk
Core offering1 text field

Numedicus is a pharmaceutical drug repurposing (therapeutic switching) company that identifies secondary clinical uses for existing drugs and licenses the resulting method-of-use patents to pharmaceutical, biotechnology, drug delivery, and academic partners. Its discovery engine is the proprietary DrugRepurposing.info database containing 9,040 compounds across 471 indications with 999 mechanisms and 4,101 repurposing opportunities, which it uses to source and advance clinical-stage candidates such as tianeptine for Rett Syndrome and espindolol for cancer cachexia.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Drug repurposing reduces R&D costs to approximately one-third to one-quarter of new chemical entity development costs
+2 more records
Product overview1 text field

Numedicus is a drug repurposing company focused on identifying secondary uses for existing drugs. The company's primary offering is the DrugRepurposing.info database, which contains 9040 compounds, 471 indications, 999 mechanisms, and provides 4101 repurposing opportunities. Numedicus uses this database to identify and develop clinical-stage candidates, licensing them to pharmaceutical partners for advancement. Key clinical programs include Tianeptine (Phase II for Rett Syndrome with AMO Pharma) and Espindolol (for cancer cachexia, via spin-out Actimed Therapeutics). The company also authored the book 'Off-Label Prescribing: Justifying Unapproved Medicine.'

Product and service4 records
1DrugRepurposing.info Database
CategoryDrug Repurposing Database
Description

An online knowledge database, owned by Numedicus, containing 9,040 compounds (launched, registered, or investigated), 471 indications, 999 mechanisms, 3,013 mechanism-indication links, 815 compound-indication links, and 273 compound-mechanism (off-target) links, yielding 4,101 repurposing opportunities. Used by the company to identify clinical-stage repurposing candidates for licensing.

2Tianeptine (Rett Syndrome Program)
CategoryRepurposed Drug Candidate (Rett Syndrome)
Description

A clinical-stage drug repurposing candidate for the treatment of Rett Syndrome (and certain breathing disorders), developed on the basis of Numedicus's IP and licensed to AMO Pharma. The treatment subsequently received FDA Orphan Drug designation.

3Espindolol (Cancer Cachexia Program)
CategoryRepurposed Drug Candidate (Cancer Cachexia)
Description

A clinical-stage beta blocker repurposed for cancer cachexia, combining three mechanisms (beta-1 adrenergic inhibition, partial beta-2 adrenergic agonism, 5-HT1A interaction). Numedicus improved on prior beta-blocker IP, filed a patent (now granted worldwide including US8716325), and contributed to the spin-out of Actimed Therapeutics to advance development.

4AMO-04 Glutamate Modulator (Licensed to AMO Pharma)
CategoryRepurposed Drug Candidate (Rett Syndrome / Breathing Disorders)
Description

A long-safety-history glutamate modulator repurposed for Rett Syndrome and certain breathing disorders, licensed by Numedicus to AMO Pharma under a Development and License Agreement along with related compound IP and know-how, with the treatment later receiving FDA Orphan Drug designation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Numedicus entered into a Development and License Agreement with AMO Pharma to advance the development of a glutamate modulator (AMO-04) and related compounds for the treatment of Rett Syndrome and certain breathing disorders. Numedicus licensed two key pieces of intellectual property and associated know-how around the use of an existing glutamate modulator. AMO Pharma is a privately held biopharmaceutical company led by CEO Mike Snape, focused on debilitating diseases with limited treatment options. The treatment subsequently received FDA Orphan Drug designation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Numedicus contributed to the formation of Actimed Therapeutics, a spin-out company for the development of espindolol for the treatment of cancer cachexia. Actimed was founded by Profs Andrew Coats and Stefan Anker, two leading cardiologists and inventors of the background intellectual property for the use of beta adrenergic blockers in cachexia treatment. Numedicus improved on this technology by identifying a single isomer of pindolol and filed a patent (now granted worldwide) for the treatment of cachexia.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Exvastat is an associated company of Numedicus, led by David Cavalla as founder. Exvastat undertook clinical research of kinase inhibitors in ARDS. In the context of Covid-19, Exvastat announced the start of a Phase II trial in severe Covid-19 patients.

4PsiOxus
Strategic tierMinorTypeStrategic or Co-development Partner
Description

PsiOxus conducted the Phase II trial of MT-102 (s-pindolol) in cancer cachexia. David Cavalla is inventor of this technology and Numedicus has an interest in this development. PsiOxus reported the positive outcome of the Phase II trial.

numedicus.co.uk
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Rettsyndrome.org sponsored the Scout Program, which screened AMO-04 (Numedicus's glutamate modulator licensed to AMO Pharma) and showed significant promise as a potential treatment for Rett Syndrome.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Arachnova Ltd was a company founded and previously run by David Cavalla, focused on therapeutic switching. Numedicus's discovery engine was initially used for Arachnova Therapeutics Limited and also for various Drug Delivery Companies in the UK and Europe.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Shadow Lake Group Inc., a boutique life sciences advisory firm based in Toronto, Canada, advised Numedicus on the transaction with AMO Pharma.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

David Cavalla is CEO and Co-founder of Serenatis Bio Ltd, a company focused on the development of new drugs for Obsessive Compulsive Disorder. This represents David Cavalla's involvement beyond Numedicus.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers8 records
1Sosei Heptares
TypeRegional player
Description

Sosei Heptares is a Japan-based GPCR-focused drug discovery company with significant UK operations and a track record of licensing deals. Comparable in pharma partnership and licensing model to Numedicus, but at a much larger scale.

TypeDirect peer
Description

Healx is an AI-driven drug repurposing company focused on rare diseases. It is comparable to Numedicus in repurposing-led drug discovery for underserved indications, though it leverages AI/ML where Numedicus uses a knowledge-based engine.

TypeDirect peer
Description

Every Cure is a non-profit drug repurposing organization leveraging AI to match existing drugs to untreated diseases. It overlaps with Numedicus's mission of identifying new indications for approved compounds, though structured as a non-profit.

4Pharnext
TypeDirect peer
Description

Pharnext is a clinical-stage biopharmaceutical company developing novel combinations of repurposed drugs, with a strong emphasis on rare neurological diseases. It mirrors Numedicus's repurposing-led development model and rare disease focus.

5Biovista
TypeDirect peer
Description

Biovista is a drug repurposing company that uses a systematic, evidence-based approach to identify new indications for existing drugs. It is directly comparable to Numedicus in business model (IP licensing to pharma) and therapeutic switching focus.

TypeDirect peer
Description

Cyclica is a computational drug discovery company using AI/ML for polypharmacology profiling and drug repurposing. Comparable to Numedicus in identifying novel indications for existing compounds via a data-driven approach.

TypeBroad incumbent
Description

Benevolent AI is a clinical-stage AI drug discovery company with a broad pipeline across multiple therapeutic areas. It competes with Numedicus for pharma AI/repurposing partnerships but operates at a far larger scale and capital base.

TypeEmerging player
Description

Cambridge, UK-based biotech developing bicycle-based therapeutics, with a Cambridge-located operating base comparable to Numedicus. Different modality but shared UK biotech ecosystem, similar early-stage licensing collaborations.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Numedicus

Pharmaceutical Drug Repurposing Consultingnumedicus.co.uk

Numedicus is a UK-based pharmaceutical company that identifies and patents secondary therapeutic uses for existing drugs, backed by its proprietary DrugRepurposing.info database of 9,040 compounds and 4,101 repurposing opportunities, and licenses these method-of-use patents to pharma and biotech partners.

What Numedicus does

Numedicus is a UK-based pharmaceutical company founded in 2008 (first posts 2009) and headquartered in Cambridge, England. The company specializes in drug repurposing (therapeutic switching), using a knowledge-based approach to identify secondary therapeutic uses for compounds that have already been launched, registered, or investigated. Its core asset is the proprietary DrugRepurposing.info database, which catalogues 9,040 compounds, 471 indications, 999 mechanisms, 3,013 mechanism-indication links, 815 compound-indication links, and 273 compound-mechanism (off-target) links, yielding 4,101 candidate repurposing opportunities. The company uses five methods to find new drug uses: bioinformatics-based mathematical association, pharmacology pathway models, off-target pharmacological screening, clinical experimentation, and a knowledge-based approach that bridges to patent-protectable aspects.

The business model is B2B IP licensing and co-development. Numedicus identifies clinical-stage repurposing candidates, secures method-of-use patents, and out-licenses them to pharmaceutical and biotech partners for further development and commercialization. Lead assets include Tianeptine / a glutamate modulator (AMO-04), licensed to AMO Pharma for Rett Syndrome and certain breathing disorders (which received FDA Orphan Drug Designation in July 2018), and espindolol for cancer cachexia, which was contributed to the 2017 Actimed Therapeutics spin-out. Numedicus also works with associated company Exvastat (David Cavalla-founded, kinase inhibitors; Phase II in severe Covid-19 initiated 2020), and historically with PsiOxus on the Phase II MT-102 program. Customer segments span large, mid-size, and specialty pharma, biotech companies seeking life-cycle management or in-licensing opportunities, university pharmacology departments with academic discoveries, drug delivery companies seeking novel actives, and rare disease / orphan drug developers.

The firm operates as a lean, asset-centric, virtual organization: founder and CEO David Cavalla leads the company while also chairing or co-founding several other biotechs (Arachnova Ltd, Exvastat, Serenatis Bio Ltd), and no external equity investors or institutional shareholders are disclosed. Revenue is generated through licensing milestones and royalty-like payments on out-licensed IP, supported by patents including EP2094254B1 (s-pindolol / cancer cachexia) and US8716325 (espindolol for cachexia). Marketing and distribution rely on the DrugRepurposing.info website, a blog covering pharmaceutical strategy and drug repurposing, a newsletter subscription, and a Twitter channel (@numedicus).

Numedicus firmographics

Firmographics
Name
Numedicus
Legal name
Numedicus Limited
Website
https://numedicus.co.uk
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
1–10 employees
Short description
Numedicus is a UK-based pharmaceutical company that identifies and patents secondary therapeutic uses for existing drugs, backed by its proprietary DrugRepurposing.info database of 9,040 compounds and 4,101 repurposing opportunities, and licenses these method-of-use patents to pharma and biotech partners.
Ownership category
akta.pro rank

Numedicus industry classification

Industry
Product category
Pharmaceutical Drug Repurposing Consulting
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Drug repurposing services
  • Therapeutic switching
  • Pharmaceutical IP licensing
  • Method-of-use patents
  • Drug discovery consulting

Where Numedicus is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Numedicus business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Licensing and IP Commercialization: Numedicus generates revenue through licensing its intellectual property (method-of-use patents) to pharmaceutical and biotechnology companies. The company identifies clinical-stage drug repurposing projects, secures patent protection, and licenses them to partners for further development. Examples include licensing to AMO Pharma (Rett Syndrome glutamate modulator) and the spin-out of Actimed Therapeutics for espindolol (cancer cachexia).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Numedicus product offering

Product offering

Core offering

Numedicus is a pharmaceutical drug repurposing (therapeutic switching) company that identifies secondary clinical uses for existing drugs and licenses the resulting method-of-use patents to pharmaceutical, biotechnology, drug delivery, and academic partners. Its discovery engine is the proprietary DrugRepurposing.info database containing 9,040 compounds across 471 indications with 999 mechanisms and 4,101 repurposing opportunities, which it uses to source and advance clinical-stage candidates such as tianeptine for Rett Syndrome and espindolol for cancer cachexia.

Product overview

Numedicus is a drug repurposing company focused on identifying secondary uses for existing drugs. The company's primary offering is the DrugRepurposing.info database, which contains 9040 compounds, 471 indications, 999 mechanisms, and provides 4101 repurposing opportunities. Numedicus uses this database to identify and develop clinical-stage candidates, licensing them to pharmaceutical partners for advancement. Key clinical programs include Tianeptine (Phase II for Rett Syndrome with AMO Pharma) and Espindolol (for cancer cachexia, via spin-out Actimed Therapeutics). The company also authored the book 'Off-Label Prescribing: Justifying Unapproved Medicine.'

Differentiator

Problem solved

Functional benefit

Brands

  • DrugRepurposing Online database: Online database featuring over 4,000 potential new uses for existing compounds, containing both existing and abandoned drugs and focused on functional, experimentally validated content. Available at drugrepurposing.info.

Products and services

  • DrugRepurposing.info Database An online knowledge database, owned by Numedicus, containing 9,040 compounds (launched, registered, or investigated), 471 indications, 999 mechanisms, 3,013 mechanism-indication links, 815 compound-indication links, and 273 compound-mechanism (off-target) links, yielding 4,101 repurposing opportunities. Used by the company to identify clinical-stage repurposing candidates for licensing.
  • Tianeptine (Rett Syndrome Program) A clinical-stage drug repurposing candidate for the treatment of Rett Syndrome (and certain breathing disorders), developed on the basis of Numedicus's IP and licensed to AMO Pharma. The treatment subsequently received FDA Orphan Drug designation.
  • Espindolol (Cancer Cachexia Program) A clinical-stage beta blocker repurposed for cancer cachexia, combining three mechanisms (beta-1 adrenergic inhibition, partial beta-2 adrenergic agonism, 5-HT1A interaction). Numedicus improved on prior beta-blocker IP, filed a patent (now granted worldwide including US8716325), and contributed to the spin-out of Actimed Therapeutics to advance development.
  • AMO-04 Glutamate Modulator (Licensed to AMO Pharma) A long-safety-history glutamate modulator repurposed for Rett Syndrome and certain breathing disorders, licensed by Numedicus to AMO Pharma under a Development and License Agreement along with related compound IP and know-how, with the treatment later receiving FDA Orphan Drug designation.

Quantifiable outcome

  • Drug repurposing reduces R&D costs to approximately one-third to one-quarter of new chemical entity development costs
  • +2 more outcomes

Companies that use Numedicus

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Numedicus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Numedicus partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • AMO PharmacoreOEM/ Whitelabel/ Licensing PartnerNumedicus entered into a Development and License Agreement with AMO Pharma to advance the development of a glutamate modulator (AMO-04) and related compounds for the treatment of Rett Syndrome and certain breathing disorders. Numedicus licensed two key pieces of intellectual property and associated know-how around the use of an existing glutamate modulator. AMO Pharma is a privately held biopharmaceutical company led by CEO Mike Snape, focused on debilitating diseases with limited treatment options. The treatment subsequently received FDA Orphan Drug designation.
  • Actimed TherapeuticscoreStrategic or Co-development PartnerNumedicus contributed to the formation of Actimed Therapeutics, a spin-out company for the development of espindolol for the treatment of cancer cachexia. Actimed was founded by Profs Andrew Coats and Stefan Anker, two leading cardiologists and inventors of the background intellectual property for the use of beta adrenergic blockers in cachexia treatment. Numedicus improved on this technology by identifying a single isomer of pindolol and filed a patent (now granted worldwide) for the treatment of cachexia.
  • ExvastatminorStrategic or Co-development PartnerExvastat is an associated company of Numedicus, led by David Cavalla as founder. Exvastat undertook clinical research of kinase inhibitors in ARDS. In the context of Covid-19, Exvastat announced the start of a Phase II trial in severe Covid-19 patients.
  • PsiOxusminorStrategic or Co-development PartnerPsiOxus conducted the Phase II trial of MT-102 (s-pindolol) in cancer cachexia. David Cavalla is inventor of this technology and Numedicus has an interest in this development. PsiOxus reported the positive outcome of the Phase II trial.
  • Rettsyndrome.orgminorStrategic or Co-development PartnerRettsyndrome.org sponsored the Scout Program, which screened AMO-04 (Numedicus's glutamate modulator licensed to AMO Pharma) and showed significant promise as a potential treatment for Rett Syndrome.
  • Arachnova LtdminorStrategic or Co-development PartnerArachnova Ltd was a company founded and previously run by David Cavalla, focused on therapeutic switching. Numedicus's discovery engine was initially used for Arachnova Therapeutics Limited and also for various Drug Delivery Companies in the UK and Europe.
  • Shadow Lake Group Inc.minorImplementation/ SI/ Consulting PartnerShadow Lake Group Inc., a boutique life sciences advisory firm based in Toronto, Canada, advised Numedicus on the transaction with AMO Pharma.
  • Serenatis Bio LtdminorStrategic or Co-development PartnerDavid Cavalla is CEO and Co-founder of Serenatis Bio Ltd, a company focused on the development of new drugs for Obsessive Compulsive Disorder. This represents David Cavalla's involvement beyond Numedicus.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Numedicus competitors and assessment

Company assessment

Regional players

  • Sosei Heptares: Sosei Heptares is a Japan-based GPCR-focused drug discovery company with significant UK operations and a track record of licensing deals. Comparable in pharma partnership and licensing model to Numedicus, but at a much larger scale.

Direct peers

  • Healx: Healx is an AI-driven drug repurposing company focused on rare diseases. It is comparable to Numedicus in repurposing-led drug discovery for underserved indications, though it leverages AI/ML where Numedicus uses a knowledge-based engine.
  • Every Cure: Every Cure is a non-profit drug repurposing organization leveraging AI to match existing drugs to untreated diseases. It overlaps with Numedicus's mission of identifying new indications for approved compounds, though structured as a non-profit.
  • Pharnext: Pharnext is a clinical-stage biopharmaceutical company developing novel combinations of repurposed drugs, with a strong emphasis on rare neurological diseases. It mirrors Numedicus's repurposing-led development model and rare disease focus.
  • Biovista: Biovista is a drug repurposing company that uses a systematic, evidence-based approach to identify new indications for existing drugs. It is directly comparable to Numedicus in business model (IP licensing to pharma) and therapeutic switching focus.
  • Cyclica: Cyclica is a computational drug discovery company using AI/ML for polypharmacology profiling and drug repurposing. Comparable to Numedicus in identifying novel indications for existing compounds via a data-driven approach.

Broad incumbents

  • Benevolent AI: Benevolent AI is a clinical-stage AI drug discovery company with a broad pipeline across multiple therapeutic areas. It competes with Numedicus for pharma AI/repurposing partnerships but operates at a far larger scale and capital base.

Emerging players

  • Bicycle Therapeutics: Cambridge, UK-based biotech developing bicycle-based therapeutics, with a Cambridge-located operating base comparable to Numedicus. Different modality but shared UK biotech ecosystem, similar early-stage licensing collaborations.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Numedicus social profiles

Digital presence

Numedicus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Numedicus leadership team

Management profile

Number of profiles

Profiles1 record

Numedicus funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Numedicus M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Numedicus

What does Numedicus do?

Numedicus is a pharmaceutical drug repurposing (therapeutic switching) company that identifies secondary clinical uses for existing drugs and licenses the resulting method-of-use patents to pharmaceutical, biotechnology, drug delivery, and academic partners. Its discovery engine is the proprietary DrugRepurposing.info database containing 9,040 compounds across 471 indications with 999 mechanisms and 4,101 repurposing opportunities, which it uses to source and advance clinical-stage candidates such as tianeptine for Rett Syndrome and espindolol for cancer cachexia.

Is Numedicus a public or private company?

Numedicus is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Numedicus founded?

Numedicus was founded in 2009. It employs 1 to 10 people.

Where is Numedicus based?

Numedicus is headquartered in Cambridge, United Kingdom, in the Europe region.

How does Numedicus make money?

One revenue line is on record: licensing and IP Commercialization.

Who are Numedicus's main competitors?

Sosei Heptares is listed as a regional player. Direct peers are Healx, Every Cure, Pharnext, Biovista and Cyclica. Benevolent AI is listed as a broad incumbent. Bicycle Therapeutics is listed as an emerging player.

Does Numedicus have an API?

No public API is recorded for Numedicus.

What industry is Numedicus in?

Numedicus's product category is Pharmaceutical Drug Repurposing Consulting. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals